Theranos’ Future Hangs On A Thread

Mark Melin

Published onApril 1, 2016

Updated on May 13, 2021

Controversial medical laboratory services company Theranos could be in the throws a crisis. Late Thursday regulators revealed the company’s high-profile blood tests failed quality control tests almost 30% of the time. The report, which was leaked to The Wall Street Journal, paints a troubling picture of a company tagged with a $9 billion valuation based on an easy and inexpensive finger-prick blood test that was promoted as revolutionary.

Elizabeth Holmes, Theranos — Elizabeth Holmes

Latest development could put company’s $9 billion valuation in jeopardy

It wasn’t long ago Theranos CEO Elizabeth Holmes was proclaiming that nearly 200...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mark Melin

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.

Theranos’ Future Hangs On A Thread

Latest development could put company’s $9 billion valuation in jeopardy

Login required to continue reading.

Get Your Business News